Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Spastic Paraplegia - Centers of Excellence Research Network
NCT06553976 · View on ClinicalTrials.gov ↗
Study Summary
The Spastic Paraplegia - Centers of Excellence Research Network (SP-CERN) is a collaborative research consortium dedicated to advancing the understanding, diagnosis, and treatment of hereditary spastic paraplegia (HSP) and primary lateral sclerosis (PLS). Aims of the consortium are to a) perform natural history studies of HSP subtypes, b) discover and validate biomarkers and clinician- and patient-reported outcome measures, c) uncover HSP's molecular pathophysiology and develop rational therapeutic targets, and d) perform sufficiently powered clinical trials. The current pilot study is aimed at enrolling 100 individuals with hereditary spastic paraplegia type 4 (SPG4) or hereditary spastic paraplegia type 5A (SPG5A).
Conditions Studied
Study Locations (11)
Massachusetts
- Boston Children's Hospital — Boston
- Massachusetts General Hospital — Boston
Texas
- Scottish Rite for Children — Dallas
- Texas Children's Hospital — Houston
Washington
- Seattle Children's Hospital — Seattle
- University of Washington School of Medicine — Seattle
Florida
- University of Miami Miller School of Medicine — Miami
Iowa
- University of Iowa Carver College of Medicine — Iowa City
Michigan
- University of Michigan School of Medicine — Ann Arbor
New York
- Columbia University - Irving Medical Center — New York
Ohio
- Cincinnati Children's Hospital Medical Center — Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-06-04 |
| Est. Completion | 2027-06-04 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06553976
The ClinicalTrials.gov registry entry for NCT06553976 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Children's Hospital, which has 752 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 9 conditions, with Neuromuscular Diseases appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06553976 reports 11 study locations spanning 8 distinct geographic areas — top geographies include Massachusetts, Texas, Washington. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06553976 about?
NCT06553976 is a clinical study titled "Spastic Paraplegia - Centers of Excellence Research Network". The Spastic Paraplegia - Centers of Excellence Research Network (SP-CERN) is a collaborative research consortium dedicated to advancing the understanding, diagnosis, and treatment of hereditary spastic paraplegia (HSP) and primary lateral sclerosis (PLS). Aims of the consortium are to a) perform nat...
What is the current status of trial NCT06553976?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2024-06-04. Estimated completion is 2027-06-04.
What conditions does trial NCT06553976 study?
This clinical trial studies the following conditions: Neuromuscular Diseases, Primary Lateral Sclerosis, Hereditary Spastic Paraplegia, Early Onset Hereditary Spastic Paraplegia, SPG4. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
Who is sponsoring clinical trial NCT06553976?
This trial is sponsored by Boston Children's Hospital, which has 752 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06553976 being conducted?
This trial has 11 study locations across Florida, Iowa, Massachusetts, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.